China National Medicines' falling ROCE and high dependence on short-term creditors could worry potential investors. The modest 32% stock gain over five years may reflect these concerns. The firm's reinvestment despite declining returns may not bode well for multi-bagger investors.
China National Medicines' reinvestment of capital hasn't significantly boosted sales and may take more time to positively impact earnings. Its declining ROCE and high liabilities make it an unlikely multi-bagger, suggesting investors look elsewhere.
国药股份股票讨论区
消息公布后,国药股份直线拉升涨停,国药一致、国药现代跟涨。
$国药股份(600511.SH)$
根据公告,中国生物将采用随机、双盲、队列研究的形式,在已完成2或3剂新冠疫苗接种的18岁及以上人群中进行序贯免疫临床研究,评价奥密克戎变异株新冠病毒灭活疫苗的安全性和免疫原性。
暂无评论